Key Points
- Director Peter Thompson sold 33,356 shares on December 24 at an average price of $44.55 for proceeds of $1,486,009.80, reducing his holding by 0.93% to 3,561,655 shares (valued about $158.7M).
- Large institutional interest: RA Capital, TPG GP A, Braidwell and Baker Bros. established positions, and Vanguard boosted its stake by 81.4% to 1,143,154 shares, signaling significant hedge fund buying.
- Sionna is trading around $42.81 with a market cap of $1.91B (50-day/200-day MAs $40.26/$28.53) and carries a consensus rating of "Moderate Buy" with a $43.14 price target amid multiple recent buy/strong-buy initiations.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Peter Thompson sold 33,356 shares of Sionna Therapeutics stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares of the company's stock, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Sionna Therapeutics Stock Down 2.0%
Sionna Therapeutics stock opened at $42.81 on Tuesday. The company's 50-day moving average price is $40.26 and its two-hundred day moving average price is $28.53. The stock has a market cap of $1.91 billion and a P/E ratio of -8.79. Sionna Therapeutics, Inc. has a twelve month low of $7.26 and a twelve month high of $45.00.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.06.
Hedge Funds Weigh In On Sionna Therapeutics
Several hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. acquired a new position in shares of Sionna Therapeutics in the 1st quarter valued at approximately $109,258,000. TPG GP A LLC bought a new stake in Sionna Therapeutics during the first quarter worth $69,925,000. Braidwell LP acquired a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at $18,770,000. Vanguard Group Inc. increased its stake in shares of Sionna Therapeutics by 81.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company's stock valued at $33,620,000 after purchasing an additional 512,803 shares during the last quarter. Finally, Baker BROS. Advisors LP acquired a new position in shares of Sionna Therapeutics during the 1st quarter worth $4,184,000.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on SION. Lifesci Capital started coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They issued an "outperform" rating and a $60.00 target price for the company. Raymond James Financial reissued a "strong-buy" rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. BTIG Research began coverage on shares of Sionna Therapeutics in a report on Wednesday, November 19th. They set a "buy" rating and a $50.00 target price on the stock. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a "buy" rating and a $46.00 price target for the company. Finally, Wall Street Zen raised Sionna Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Sionna Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $43.14.
View Our Latest Analysis on Sionna Therapeutics
About Sionna Therapeutics
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
